Genomic complexity of multiple myeloma and its clinical implications

Nature Reviews Clinical Oncology

Volumn 14, Issue 2, 2017, Pages 100-113

  Manier, Salomon ^a,b   Salem, Karma Z ^a,b   Park, Jihye ^a,b   Landau, Dan A ^c,d   Getz, Gad ^b,e   Ghobrial, Irene M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c NEW YORK GENOME CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MONOCLONAL ANTIBODY; OSTEOPROTEGERIN; GENETIC MARKER;

CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CLONAL EVOLUTION; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE COURSE; DNA DAMAGE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HUMAN; KARYOTYPING; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OSTEOLYSIS; OVERALL SURVIVAL; PROTEIN ELECTROPHORESIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR GROWTH; CHROMOSOME DELETION; DIPLOIDY; GENE TRANSLOCATION; GENETIC MARKER; GENETICS; GENOMICS; HUMAN GENOME; MUTATION; PROGNOSIS;

CHROMOSOME DELETION; CLONAL EVOLUTION; DIPLOIDY; DNA COPY NUMBER VARIATIONS; GENETIC HETEROGENEITY; GENETIC MARKERS; GENOME, HUMAN; GENOMICS; HUMANS; MULTIPLE MYELOMA; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TRANSLOCATION, GENETIC;

EID: 84983035375     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2016.122     Document Type: Review

References (130)

1. Palumbo, A., & Anderson, K. Multiple myeloma. N. Engl. J. Med. 364, 1046-1060 (2011
2. Howlader, N., et al. SEER Cancer Statistics Review, 1975-2013. SEER web site [online] http://seer.cancer. gov/csr/1975-2013/(2016
3. Landgren, O., et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113, 5412-5417 (2009
4. Weiss, B. M., Abadie, J., Verma, P., Howard, R. S., & Kuehl, W. M. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113, 5418-5422 (2009
5. Chapman, M. A., et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472 (2011
6. Lohr, J. G., et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91-101 (2014
7. Bolli, N., et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat. Commun. 5, 2997 (2014
8. Walker, B. A., et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nature Commun. 6, 6997 (2015
9. Walker, B. A., et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J. Clin. Oncol, http://dx.doi.org/10.1200/JCO.2014.59.1503 (2015
10. Altieri, A., Chen, B., Bermejo, J. L., Castro, F., & Hemminki, K. Familial risks and temporal incidence trends of multiple myeloma. Eur. J. Cancer 42, 1661-1670 (2006
11. Broderick, P., et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat. Genet. 44, 58-61 (2012
12. Chubb, D., et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat. Genet. 45, 1221-1225 (2013
13. Weinhold, N., et al. Inherited genetic susceptibility to monoclonal gammopathy of unknown significance. Blood 123, 2513-2517; quiz 2593, http://dx.doi.org/10.1182/blood-2013-10-532283 (2014
14. Weinhold, N., et al. The CCND1 c.870GA polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat. Genet. 45, 522-525 (2013
15. Johnson, D. C., et al. Genetic factors influencing the risk of multiple myeloma bone disease. Leukemia, http://dx.doi.org/10.1038/leu.2015.342 (2015
16. Swaminathan B., et al. Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. Nat. Commun. 6, 7213 (2015
17. Ziv, E., et al. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nat. Commun. 6, 7539 (2015
18. Landgren, O., et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia 28, 1537-1542 (2014
19. Gonzalez, D., et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 110, 3112-3121 (2007
20. Bergsagel, P. L., et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106, 296-303 (2005
21. Ross, F. M., et al. Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia 19, 1634-1642 (2005
22. Kaufmann, H., et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia 18, 1879-1882 (2004
23. Fonseca, R., et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 100, 1417-1424 (2002
24. Avet-Loiseau, H., et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone Myelome. Cancer Res. 59, 4546-4550 (1999
25. Chesi, M., et al. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88, 674-681 (1996
26. Tanguay, D. A., & Chiles, T. C. Regulation of the catalytic subunit (p34PSK J3/cdk4) for the major D type cyclin in mature B lymphocytes. J. Immunol. 156, 539-548 (1996
27. Solvason, N., et al. Induction of cell cycle regulatory proteins in anti-immunoglobulin-stimulated mature B lymphocytes. J. Exp. Med. 184, 407-417 (1996
28. Walker, B. A., et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood 121, 3413-3419 (2013
29. Zhan, F., et al. The molecular classification of multiple myeloma. Blood 108, 2020-2028 (2006
30. Keats, J. J., et al. In multiple myeloma, t(4;14) (p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101, 1520-1529 (2003
31. Fonseca, R., et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101, 4569-4575 (2003
32. Chang, H., et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br. J. Haematol. 125, 64-68 (2004
33. Avet-Loiseau, H., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 109, 3489-3495 (2007
34. Chesi, M., et al. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 92, 3025-3034 (1998
35. Santra M., Zhan, F., Tian, E., Barlogie, B., & Shaughnessy, J. Jr. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 101, 2374-2376 (2003
36. Keats, J. J., et al. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood 105, 4060-4069 (2005
37. Martinez-Garcia, E., et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 117, 211-220 (2011
38. Pei, H., et al. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 470, 124-128 (2011
39. Cappellen, D., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nature Genet. 23, 18-20 (1999
40. San Miguel, J. F., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359, 906-917 (2008
41. Avet-Loiseau, H., et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J. Clin. Oncol. 28, 4630-4634 (2010
42. Hanamura, I., et al. Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations. Jpn. J. Cancer Res. 92, 638-644 (2001
43. Hurt, E. M., et al. Overexpression of c maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5, 191-199 (2004
44. Avet-Loiseau, H., et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood 117, 2009-2011 (2011
45. Prideaux, S. M., Conway O'Brien, E., & Chevassut, T. J. The genetic architecture of multiple myeloma. Adv. Hematol. 2014, 864058 (2014
46. Shaughnessy Jr. J. et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 98, 217-223 (2001
47. Mikhael, J. R., et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin. Proc. 88, 360-376 (2013
48. Ross, F. M., et al. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-Term stable disease in monoclonal gammopathies of undetermined significance. Haematologica 95, 1221-1225 (2010
49. Avet-Loiseau, H., et al. Rearrangements of the c myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 98, 3082-3086 (2001
50. Weinhold, N., et al. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica http://dx.doi.org/10.3324/haematol.2015.136929 2015
51. Haradhvala, N. J., et al. Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair. Cell 164, 538-549 (2016
52. Affer, M., et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia 28, 1725-1735 (2014
53. Walker, B. A., et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer J. 4, e191 (2014
54. Carrasco, D. R., et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9, 313-325 (2006
55. Walker, B. A., et al. A compendium of myeloma-Associated chromosomal copy number abnormalities and their prognostic value. Blood 116, e56-65 (2010
56. Walker, B. A., et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 108, 1733-1743 (2006
57. Annunziata, C. M., et al. Frequent engagement of the classical and alternative NF kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115-130 (2007
58. Keats, J. J., et al. Promiscuous mutations activate the noncanonical NF kappaB pathway in multiple myeloma. Cancer Cell 12, 131-144 (2007
59. Smadja, N. V., et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 12, 960-969 (1998
60. Debes-Marun, C. S., et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 17, 427-436 (2003
61. Chng, W. J., et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 106, 2156-2161 (2005
62. Onodera, N., McCabe, N. R., & Rubin, C. M. Formation of a hyperdiploid karyotype in childhood acute lymphoblastic leukemia. Blood 80, 203-208 (1992
63. Fonseca, R., et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 102, 2562-2567 (2003
64. Pawlyn, C., et al. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood 125, 831-840 (2015
65. Chng, W. J., et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 67, 2982-2989 (2007
66. Smadja, N. V., et al. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98, 2229-2238 (2001
67. Chretien, M. L., et al. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? Blood 126, 2713-2719 (2015
68. Shaughnessy, J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 10 (Suppl. 1), 117-126, http://dx.doi.org/10.1080/10245330512331390140 (2005
69. Sawyer, J. R., Tricot, G., Mattox, S., Jagannath, S., & Barlogie, B. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood 91, 1732-1741 (1998
70. Sawyer, J. R., et al. Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood 123, 2504-2512 (2014
71. Fournier, A., et al. 1q12 chromosome translocations form aberrant heterochromatic foci associated with changes in nuclear architecture and gene expression in B cell lymphoma. EMBO Mol. Med. 2, 159-171 (2010
72. Shi, L., et al. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget 1, 22-33 (2010
73. Hanamura, I., et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108, 1724-1732 (2006
74. Boyd K. D., et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin. Cancer Res.17, 7776-7784 2011
75. Chang, H., et al. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Leuk. Lymphoma 51, 2084-2091 (2010
76. Avet-Loiseau, H., et al. Prognostic significance of copy-number alterations in multiple myeloma. J. Clin. Oncol. 27, 4585-4590 (2009
77. Chang, H., et al. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant. 45, 117-121 (2010
78. Fonseca, R., et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 15, 981-986 (2001
79. Avet-Loiseau, H., et al. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone Myelome. Blood 94, 2583-2589 (1999
80. Chiecchio, L., et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 20, 1610-1617 (2006
81. Avet-Louseau, H. Daviet, A., Sauner, S., Bataille, R., & Intergroupe Francophone du Myélome. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br. J. Haematol. 111, 1116-1117 (2000
82. Fonseca, R., et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23, 2210-2221 (2009
83. Tricot, G., et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86, 4250-4256 (1995
84. Tiedemann, R. E., et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 22, 1044-1052 (2008
85. Lode, L., et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica 95, 1973-1976 (2010
86. Drach, J., et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 92, 802-809 (1998
87. Palumbo, A., et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J. Clin. Oncol. 33, 2863-2869 (2015
88. Beroukhim, R., et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl Acad. Sci. USA 104, 20007-20012 (2007
89. Beroukhim, R., et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010
90. Zack, T. I., et al. Pan-cancer patterns of somatic copy number alteration. Nature Genet. 45, 1134-1140 (2013
91. Lawrence, M. S., et al. Mutational heterogeneity in cancer and the search for new cancer-Associated genes. Nature 499, 214-218 (2013
92. Lawrence, M. S., et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014
93. Alexandrov, L. B., et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013
94. Nik-Zainal, S., et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012
95. Weber, A. M., & Ryan, A. J. ATM and ATR as therapeutic targets in cancer. Pharmacol. Ther. 149, 124-138 (2015
96. Dziembowski, A., Lorentzen, E., Conti, E., & Seraphin, B. A single subunit, Dis3, is essentially responsible for yeast exosome core activity. Nat. Struct. Mol. Biol. 14, 15-22 (2007
97. Schmid, M., & Jensen, T. H. The exosome: a multipurpose RNA-decay machine. Trends Biochem. Sci. 33, 501-510 (2008
98. Weissbach, S., et al. The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma. Br. J. Haematol. 169, 57-70 (2015
99. Tam, W., et al. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B cell lymphomas. Blood 107, 4090-4100 (2006
100. Pasqualucci, L., et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J. Exp. Med. 203, 311-317 (2006
101. Landau, D. A., Carter, S. L., Getz, G., & Wu, C. J. Clonal evolution in hematological malignancies and therapeutic implications. Leukemia 28, 34-43 (2014
102. Anderson, K., et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356-361 (2011
103. Bahlis, N. J. Darwinian evolution and tiding clones in multiple myeloma. Blood 120, 927-928 (2012
104. Carter, S. L., et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012
105. Landau, D. A., et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726 (2013
106. Melchor, L., et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia 28, 1705-1715 (2014
107. Smadja, N. V., et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer 38, 234-239 (2003
108. Walker, B. A., et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 28, 384-390 (2014
109. Greipp, P. R., et al. International staging system for multiple myeloma. J. Clin. Oncol. 23, 3412-3420 (2005
110. Andrulis, M., et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 3, 862-869 (2013
111. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-Type BRAF. Nature 464, 427-430 (2010
112. Lonial, S., et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J. Clin. Oncol. 30, 1953-1959 (2012
113. Jakubowiak, A. J., et al. Phase I trial of anti CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J. Clin. Oncol. 30, 1960-1965 (2012
114. Lokhorst, H. M., et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N. Engl. J. Med. 373, 1207-1219 (2015
115. Lonial, S., et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387, 1551-1560 (2016
116. Carpenter R. O., et al. B Cell maturation antigen is a promising target for adoptive T cell therapy of multiple myeloma. Clin. Cancer Res.19, 2048-2060 2013
117. Ramos, C. A., et al. Clinical responses with T lymphocytes targeting malignancy-Associated kappa light chains. J. Clin. Invest. http://dx.doi.org/10.1172/JCI86000 (2016
118. Lesokhin A. M., et al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2015.65.9789 (2016
119. Herbst, R. S., et al. Predictive correlates of response to the anti PD L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014
120. Schumacher, T. N., & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69-74 (2015
121. Greaves, M., & Maley, C. C. Clonal evolution in cancer. Nature 481, 306-313 (2012
122. Hanahan, D., & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011
123. Janne, P. A., et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 14, 38-47 (2013
124. Adjei, A. A., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-Activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY 142886) in patients with advanced cancers. J. Clin. Oncol. 26, 2139-2146 (2008
125. Abdel-Wahab, O., et al. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF-And NRAS-mutant malignancies. Cancer Discov. 4, 538-545 (2014
126. Filippakopoulos, P., et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010
127. Guagnano, V., et al. FGFR genetic alterations predict for sensitivity to NVP BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2, 1118-1133 (2012
128. Gavine, P. R., et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 72, 2045-2056 (2012
129. Flaherty, K. T., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010
130. Baughn, L. B., et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 66, 7661-7667 (2006